New Probiotic-Derived Peptide Fights H. pylori Stomach Infections
Novel antimicrobial peptide FxCy2 from Lactobacillus paracasei shows clear inhibitory activity against H. pylori and synergistic effects with existing antibiotics.
Quick Facts
What This Study Found
FxCy2, a novel AMP from Lactobacillus paracasei FX-6, inhibited H. pylori (MIC = 1.25 mg/mL) and demonstrated synergistic antibacterial effects with clinical antibiotics.
Key Numbers
How They Did This
Isolation and purification of FxCy2 from Lactobacillus paracasei FX-6 fermentation supernatant, with MIC determination and synergy testing with clinical antibiotics against H. pylori.
Why This Research Matters
H. pylori infects half the world's population and antibiotic resistance is rising. A probiotic-derived peptide that enhances existing antibiotics could improve treatment outcomes.
The Bigger Picture
Probiotic-derived antimicrobials that work synergistically with existing drugs represent a practical near-term strategy to combat antibiotic resistance in common infections.
What This Study Doesn't Tell Us
In vitro study — in vivo efficacy in the acidic stomach environment not tested. MIC of 1.25 mg/mL is relatively high. Stability and delivery need optimization.
Questions This Raises
- ?Does FxCy2 remain active in the acidic environment of the stomach?
- ?Could FxCy2 be developed as an adjunct to standard H. pylori triple therapy?
Trust & Context
- Key Stat:
- MIC 1.25 mg/mL + synergy FxCy2 inhibits H. pylori alone and enhances clinical antibiotic activity when combined
- Evidence Grade:
- In vitro antimicrobial study — demonstrates proof of concept for a novel anti-H. pylori peptide but lacks in vivo data.
- Study Age:
- Published in 2026; addresses the growing H. pylori antibiotic resistance crisis.
- Original Title:
- A novel antimicrobial peptide FxCy2 against Helicobacter pylori: Isolation and purification from Lactobacillus paracasei FX-6.
- Published In:
- Food research international (Ottawa, Ont.), 225, 118069 (2026)
- Authors:
- Bi, Bo, Kang, Meng, Lin, Qianru, Wang, Qun, Li, Xiaoqing, Ye, Zhuming, Ho, Chi-Tang, Cao, Yong
- Database ID:
- RPEP-14879
Evidence Hierarchy
Frequently Asked Questions
What is H. pylori?
Helicobacter pylori is a bacterium that infects the stomach lining, causing ulcers and increasing cancer risk. It affects about half the global population and is becoming increasingly resistant to antibiotics.
How can probiotics help fight stomach infections?
Probiotic bacteria naturally produce antimicrobial peptides that can kill pathogens. FxCy2 from Lactobacillus not only fights H. pylori directly but also makes existing antibiotics work better against it.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14879APA
Bi, Bo; Kang, Meng; Lin, Qianru; Wang, Qun; Li, Xiaoqing; Ye, Zhuming; Ho, Chi-Tang; Cao, Yong. (2026). A novel antimicrobial peptide FxCy2 against Helicobacter pylori: Isolation and purification from Lactobacillus paracasei FX-6.. Food research international (Ottawa, Ont.), 225, 118069. https://doi.org/10.1016/j.foodres.2025.118069
MLA
Bi, Bo, et al. "A novel antimicrobial peptide FxCy2 against Helicobacter pylori: Isolation and purification from Lactobacillus paracasei FX-6.." Food research international (Ottawa, 2026. https://doi.org/10.1016/j.foodres.2025.118069
RethinkPeptides
RethinkPeptides Research Database. "A novel antimicrobial peptide FxCy2 against Helicobacter pyl..." RPEP-14879. Retrieved from https://rethinkpeptides.com/research/bi-2026-a-novel-antimicrobial-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.